<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02282137</url>
  </required_header>
  <id_info>
    <org_study_id>Ga PSMA124388</org_study_id>
    <secondary_id>IND124388</secondary_id>
    <nct_id>NCT02282137</nct_id>
  </id_info>
  <brief_title>68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer</brief_title>
  <acronym>PSMA</acronym>
  <official_title>68Ga-PSMA (ProstaMedixâ„¢) PET-CT Scan for Diagnosis and Management of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ebrahim Delpassand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radiomedix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Excel Diagnostics and Nuclear Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radio Isotope Therapy of America</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single center, Prospective, Phase II expanded access clinical studies of 68Ga-PSMA
      (ProstaMedix TM) used for diagnosis and management of patients with prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this trial is to evaluate patients with suspected prostate cancer recurrence and
      non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging
      (MRI). 68Ga-PSMA PET/CT imaging may help identify potential sites of prostate cancer
      recurrence for subsequent histologic confirmation. Suspected prostate recurrence will be
      based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The evidence of suspected or clinically confirmed prostate cancer confirmed by 68Ga-PSMA PET/CT.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-PSMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluation of concordance and discordance between the results of 68Ga-PSMA PET/CT and other available conventional imaging modalities (such as CT, MRI, FDG, NaF scan), histology or follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-PSMA</intervention_name>
    <description>Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.</description>
    <arm_group_label>68Ga-PSMA</arm_group_label>
    <other_name>68Ga-HBED-CC-PSMA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Male patients, aged 18 years.

          -  Histologically and/or clinically confirmed and/or suspicious of Prostate cancer.

          -  Recent Blood test results up to 4.6 weeks as follows: WBC: &gt;2*109/L, Haemoglobin:
             &gt;8.0g/Dl, Platelets: &gt;50x109/L

        Exclusion Criteria:

          -  Known hypersensitivity to 68Ga, HBED-CC, PSMA or to any of the excipients of
             68Ga-PSMA.

          -  Current somatic or psychiatric disease/condition that may interfere with the
             objectives and assessments of the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ebrahim S Delpassand, MD</last_name>
    <role>Study Director</role>
    <affiliation>RITA Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tannaz Armaghany, MD</last_name>
    <phone>713-523-6700</phone>
    <email>tarm@westcca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Radio- Isotope Therapy of America</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ebrahim S Delpassand, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ebrahim S Delpassand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radio-Isotope Therapy of America</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gelareh Vahdati</last_name>
      <email>gvahdati@exceldiagnostics.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>RITA Foundation</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Cork</last_name>
      <phone>713-341-3203</phone>
      <email>scork@exceldiagnostics.com</email>
    </contact>
    <contact_backup>
      <last_name>Izabela Tworowska, PhD</last_name>
      <phone>8328682812</phone>
      <email>itworowska@radiomedix.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tannaz Armaghany, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>November 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2014</study_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Radio Isotope Therapy of America</investigator_affiliation>
    <investigator_full_name>Ebrahim Delpassand</investigator_full_name>
    <investigator_title>Chairman and Medical Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

